

Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009

January 16, 2009 4:17 PM ET

Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 16, 2009--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and year end 2008 financial results will be released on Tuesday, January 27, 2009, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead will webcast a conference call live on the company's internet site. The call will be led by Gilead management, who will discuss the financial results for the company's fourth quarter and full year 2008, provide a general business update and review financial guidance for 2009.

To access the webcast via the internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-800-901-5247 (U.S.) or 1-617-786-4501 (international) and dial the participant passcode 74401137 to access the call. Telephone replay is available approximately two hours after the call through 6:30 p.m. Eastern Time, January 30, 2009. To access the replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 89437661. The webcast will be archived on www.gilead.com for one year.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.

Susan Hubbard, 650-522-5715

Investor Relations

Source: Gilead Sciences, Inc.